Nasdaq NDAQ
Financial Services · Financial - Data & Stock Exchanges · Synthos Deep Dive · 2026-07-03
The Overview
Nasdaq is not just "the stock exchange." Yes, it runs the Nasdaq stock market where companies list and shares trade — but the bigger story now is software it sells to banks: anti-fraud and anti-money-laundering tools (Verafin), trading and risk software (Calypso, AxiomSL), and financial indexes (the Nasdaq-100 that ETFs track). A lot of that is subscription revenue that shows up every year like clockwork — which is what makes the business better than a plain exchange.
Is the stock cheap or expensive? Moderately cheap for its quality. It has fallen about 16% from its high and now trades at roughly 19 times next year's expected earnings — reasonable for a company growing profits in the low teens. Our verdict is Buy — Tactical: a decent value in a good business, but we're not pounding the table, partly because the stock is in a downtrend and carries a fair amount of debt.
Here is what our three scores mean in plain words:
- Downside Risk 5/10 (middle). Steady, sticky revenue and a wide moat — but it borrowed heavily to buy Adenza, and the price chart is falling, not rising.
- Growth Quality 7/10 (good, not great). Profits grow reliably in the low-to-mid teens with strong margins; solid, but not a rocket.
- Exponential Potential 4/10 (low-moderate). This is a "get a little richer slowly" compounder, not a "double overnight" name. Growth is actually slowing, not speeding up.
The one big worry: if trading volumes and new-software sales slow at the same time, the debt makes the earnings swing more — and the stock is already drifting down, so patience may be required.
Important honesty note: unlike some names we cover, no outside expert in our research library has written about Nasdaq. This verdict is built purely from the financial statements and the numbers — we are not borrowing anyone else's conviction.
Putting a number on it: our fair-value estimate is $98 against a current price of $99.31 — consistent with our call to stay away or wait for a better setup.
Our summary metrics
Beta ~1.0, net-debt/EBITDA 2.85× and 25× trailing — sturdy recurring model but leveraged and in a downtrend.
~14% forward EPS CAGR, 55% gross margin, sticky SaaS ARR (+13%), high ROE — durable but not explosive.
Wide-moat compounder, not an exponential; growth decelerating and $48B cap in a mature-ish TAM caps the multibagger.
What does “fair value” mean?
Fair value is Synthos’s estimate of what one share is worth today, based on our model of the company’s future cash generation and the risks to it. It is not a price target or a prediction of where the stock trades next quarter — it’s the price where we think risk and reward are balanced. Above it, you’re paying for outcomes better than our base case; below it, the market is offering a margin of safety.
The model’s inputs and weightings are proprietary — they’re the product. What we publish is the output, plus an independent, public-math cross-check further down the page (“Check our number”) so you can judge it for yourself.
What do the 5 tiers mean? (Core · Tactical · Watch · Hold · Avoid)
Exponential Potential
Wide-moat compounder, not an exponential; growth decelerating and $48B cap in a mature-ish TAM caps the multibagger.
What could take this further than the base case — and where the market may be underpricing it. Full forward-growth and acceleration math in Deeper analysis, §4 below.
Deeper analysis
Technicals, fundamentals, valuation, and the full expert-claim evidence panel — the detail behind the numbers above.
Reference table
| Street consensus | $113.83 (high $120 / low $109; 22 Buy · 13 Hold · 1 Sell) — context, not our anchor |
| Valuation | 25× trailing EPS · 21× FY26E · 19× FY27E · 14× FY30E · EV/EBITDA 18.2× · EV/S (net) ~11× |
| Technicals | Downtrend — $84.7, −16% off 52-wk high, below 50/200-DMA, RSI 46, −4.8% 12-mo (SPY +20.6%) |
| Conviction | Moderate — 0 expert voices in the KB; verdict rests on fundamentals + quant only |
| Position sizing | Satellite / value-compounder, ~2–3% — a re-rating candidate, not a core conviction moonshot |
What the experts actually said
No independent expert claims in the Synthos knowledge base yet for NDAQ — this dive is fundamentals- and technicals-driven, not panel-driven.
Price & moving averages 12 months · 50 & 200-day averages · 52-week range
Solid line = price · dashed line = 50-day average · dotted line = 200-day average · the two thin horizontal lines mark the 52-week high and low. Price above both averages is an uptrend.
Data summary: last close $99.31, 9% above the 50-day average ($91), 10% above the 200-day average ($90) — an uptrend. 2% below the 52-week high of $101, 29% above the 52-week low of $77.
Bollinger Bands 20-day average ± 2 standard deviations
The shaded band widens when the stock gets more volatile. Riding the upper edge = strong momentum (sometimes stretched); the lower edge = weak / potentially oversold.
Data summary: price $99.31 is currently inside the band (band $93–$100).
RSI (14) momentum gauge · 0–100
Above 70 (overbought zone, shaded) = overbought, below 30 (oversold zone, shaded) = oversold. Currently 69.
MACD 12 / 26 / 9 · trend & momentum
The MACD line crossing above the signal line (bars flip to the up color) = momentum turning up; crossing below (bars flip to the down color) = turning down. Bar height = the size of that gap.
Data summary: MACD is currently above its signal line by 0.02, positive momentum.
Relative performance vs S&P 500 & its sector (XLF (sector)), set to 100 a year ago
Solid = NDAQ · dashed = S&P 500 · dotted = XLF (sector). A rising line means it is beating that benchmark — the sector line shows whether it is a leader or laggard within its own group.
Forward revenue & earnings actual → estimate · "FY" = fiscal year, "E" = estimate
Darker bars = actual results, brighter = analyst estimates. Taller bars to the right = expected growth.
Key stats an RIA wants
1. What it is
Nasdaq, Inc. (NASDAQ: NDAQ) is a ~$48B financial-infrastructure company. Once known primarily as the operator of The Nasdaq Stock Market, it has spent the last decade — capped by the $10.5B Adenza acquisition (Calypso + AxiomSL, closed 2023) and the earlier Verafin deal — reshaping itself into a recurring-revenue software-and-data business wrapped around a still-cyclical trading franchise. Fiscal year ends December 31. CEO Adena Friedman.
Revenue mix (FY2025, from filings). A note on how Nasdaq reports: FMP's income statement shows gross revenue of $8.22B, which includes transaction-based expenses (rebates/fees passed through the Market Services exchange business). Management and the Street focus on net revenue (~$4.9B FY25 run-rate; $1.41B in Q1'26), which strips out those pass-throughs. We use gross figures where the data feed does, and flag net where it matters.
- By division (gross, FY2025 segmentation): Market Services $4.21B, Capital Access Platforms $2.14B, Financial Technology / Market Technology $1.85B. On a net basis, the non-trading "Solutions" businesses (FinTech + Capital Access) are now the majority of net revenue and nearly all of the recurring base.
- The recurring engine: Annualized Recurring Revenue (ARR) $3.2B, +13% YoY (Q1'26), with SaaS at 38% of ARR. This is the number that matters most — it is what separates today's Nasdaq from a pure exchange.
- By geography (net, FY2025): United States $5.95B (72%), Non-US $2.32B (28%). US-concentrated, with international as the growth vector.
The strategic frame management uses is "Expand, Evolve, Transform" — expand the index/data franchise, evolve the exchange, and transform banks' back offices with FinTech (anti-financial-crime, regulatory, capital-markets software).
2. The expert thesis — why the panel is bullish (traceable)
There is no expert coverage of NDAQ in the Synthos knowledge base. total_claims = 0, breadth = 0, net conviction = 0. No net-bullish voices, no cautionary voice — the name simply has not been written up by any of the tracked analysts in our library.
What that means for this note, stated plainly: this verdict is entirely fundamentals- and quant-driven. We are not borrowing, blending, or citing anyone's conviction, because there is none to cite. Every judgment below is reconstructed from the financial statements, the analyst estimate consensus (FMP), and management's own earnings release. Where other Synthos deep dives lean on a panel of independent voices to corroborate the math, NDAQ has no such corroboration — treat the conviction as Moderate accordingly, and weight the raw numbers, not our narrative.
3. Synthos scores & the Bull / Base / Bear cases
The one-glance judgment — three scores, 0–10, each anchored to real metrics (not probabilities we can't honestly calibrate):
| Score | 0–10 | The read |
|---|---|---|
| Downside Risk (lower = safer) | 5 · Moderate | Sticky ARR and a wide moat cut business risk, but net-debt/EBITDA 2.85×, beta ~0.97, and a live −16% drawdown below both moving averages keep this mid-pack, not "safe." |
| Growth Quality | 7 · Good | ~14% forward EPS CAGR, 55% gross margin, ROE ~16%, ROIC ~7%, and a recurring 13% ARR grower — durable and high-quality, but not a hyper-grower. |
| Exponential Potential | 4 · Low-Moderate | Growth is decelerating (revenue growth slows toward high-single/low-double digits by FY28E), the model is mature-ish, and a $48B cap in exchange/data limits the multibagger. |
The three cases (our own scenario model — assumptions shown; each target is a ~12–18-month fair value). We deliberately do not attach probabilities: the base case is by definition the expected path, so a weighted blend would just restate it with false precision. The cases bound the range; the scores summarize them.
| Case | Key assumptions | Fair value |
|---|---|---|
| Bull | FinTech/ARR keeps compounding mid-teens, index inflows accelerate, deleveraging lifts confidence. FY27E EPS beats to ~$4.75 (vs $4.45 cons); multiple re-rates to ~25× as the "software, not exchange" narrative sticks. | ~$120 (+42%) |
| Base (our anchor) | Estimates roughly hit — FY27E EPS $4.45; a durable low-teens compounder with sticky ARR earns a ~22× multiple. | ~$98 (+16%) |
| Bear | Market-volume slump hits Market Services, FinTech bookings slow, and leverage amplifies the miss. FY27E EPS misses to ~$4.00; multiple de-rates to ~17×. | ~$70 (−17%) |
Synthos fair value = the base case, ~$98 (+16%), with the full $70–$120 span as the honest range. Our base sits below the Street's $113.83 consensus — we are less willing than the sell side to underwrite a full re-rating while the chart is falling and leverage is elevated. Our bull matches the Street high ($120); our bear ($70) prices a cyclical volume/booking air-pocket the Street largely ignores. This is a tracked call — the Forecaster Scorecard grades it once it matures.
4. Exponential Potential
Synthos separates compounders (durable high returns on capital) from exponentials (accelerating, multi-baggers-from-here). NDAQ is a solid compounder with limited exponential character:
- Forward growth: net-revenue CAGR roughly high-single-digits; EPS CAGR FY25→FY30E ~14% (GAAP EPS $3.13 → ~$6.05E) as operating leverage and buybacks help. Good, not explosive.
- Acceleration (the 2nd derivative) is negative: Street revenue growth decelerates from the mid-teens today toward high-single/low-double digits by FY28E (est revenue $5.77B FY26E → $6.26B FY27E → $6.77B FY28E → $7.27B FY29E). The Adenza-integration surge is normalizing; from here Nasdaq settles into a steady low-teens earnings compounder. Per our flagship philosophy we prize forward accelerating names — NDAQ is the opposite profile, a decelerating quality compounder.
- Room to run: the anti-financial-crime and regtech TAMs are real and expanding (Verafin's SMB and Tier-1 bank wins, Agentic AI workforce with 500+ clients), which supports durable mid-teens FinTech growth — but at $48B in a mature exchange/data industry, a 3–5× from here is not the realistic base case.
- Reinvestment runway: modest capex (~3% of revenue), heavy free-cash generation ($1.99B FY25 FCF) directed at deleveraging + buybacks + dividend rather than reinvestment-for-hypergrowth. That is the right call for this ROIC, but it is a compounder's capital plan, not an exponential's.
Exponential Potential: Low-Moderate (4/10). Own NDAQ for durable ~14% earnings compounding and a sticky, widening moat — not for a fast multibagger. This honest framing is why it lands in the satellite/value sleeve, not a Degen or high-conviction-core tier.
5. Financials (real numbers — FMP annual/quarterly)
- Revenue (gross, as reported by feed): FY25 $8.22B, +11% (FY24 $7.40B, +22% on FY23 $6.06B). On a net-revenue basis management reports ~$4.9B FY25 and +14% YoY in Q1'26 — the cleaner growth read.
- Quarterly net-revenue trajectory: Q1'26 net revenue $1.407B, +14% YoY (organic +13%), with Solutions +14% and Market Services +13%. Double-digit growth across all three divisions.
- Margins: gross ~55% TTM, EBITDA margin ~38% TTM, operating ~29.5%, net ~23% TTM. Healthy and stable; the recurring mix supports margin durability.
- Earnings: GAAP net income $1.79B FY25 (EPS $3.13, diluted $3.09), up sharply from $1.12B FY24 as Adenza-related and one-time costs normalized. Non-GAAP diluted EPS $0.96 in Q1'26, +22% YoY.
- Cash flow: operating CF $2.26B, capex ~−$266M (3.4% of gross revenue), FCF $1.99B FY25 — a ~4.2% FCF yield. Cash conversion is strong (income quality 1.19×).
- Balance sheet: total debt $9.93B, net debt $9.11B, net-debt/EBITDA 2.85× — meaningfully levered from the Adenza deal, though management is actively deleveraging (Q1'26: "reducing leverage"). Interest coverage ~13.9×; investment-grade and serviceable, but this is the single biggest risk multiplier.
6. Valuation — priced in or room?
NDAQ is reasonably priced for its quality after the drawdown. Trailing metrics: 25× GAAP EPS, ~11× net sales, 18.2× EV/EBITDA. The forward path compresses the multiple quickly even at a flat price if estimates hit: forward P/E 21× (FY26E $3.95) → 19× (FY27E $4.45) → 16× (FY28E $5.10) → 14× (FY30E $6.05). A PEG around 1.4–1.5 (forward) on a wide-moat recurring-revenue franchise is not demanding.
The catch is that the multiple has already de-rated with the −16% drawdown, and leverage means EPS is more volume-sensitive than the headline suggests. Street targets (context): consensus $113.83, high $120, low $109 — notably, the entire Street target range sits above today's $84.66, implying the sell side sees 29–42% upside. We are deliberately more conservative: our $98 base gives partial credit to that re-rating but discounts it for the downtrend and leverage. Not a deep-value screen; a quality-compounder-at-a-fair-price with a de-rated multiple that could re-rate on execution.
7. Technicals (from the tech block)
- Trend: down. $84.66 sits below the 50-DMA ($87.80) and 200-DMA ($89.04), with the 50 below the 200 — a bearish (death-cross-adjacent) posture. MACD −2.18 (negative).
- Location: −16.2% off the 52-week high ($100.98), only +10.2% off the 52-week low ($76.85) — nearer the lows than the highs, and the current 16% drawdown is the max drawdown from peak.
- Momentum: RSI(14) 46 — neutral-to-soft, neither oversold nor with upward thrust. No momentum tailwind.
- Relative strength (the tell): NDAQ −4.8% 12-mo vs SPY +20.6% and QQQ +30.3%; −0.6% 3-mo vs SPY +13.7%. Persistent, broad underperformance of both the market and the Nasdaq-100 it operates.
- Read: technicals do not confirm the fundamental thesis. This is a falling knife in relative terms — the fundamentals argue value, but the price action argues patience. A tactical buyer should scale in and would ideally want price to reclaim the 50-DMA (~$88) before adding aggressively. This tension is exactly why the verdict is Tactical, not Core.
8. Moat & competitive position
Nasdaq's moat is a genuine triple: (1) regulatory/network-effect exchange licenses and the Nasdaq brand — hard to replicate, deeply embedded; (2) index IP — the Nasdaq-100 franchise (new BlackRock and State Street partnerships, $836B ETP AUM, record $877B average) throws off high-margin, recurring licensing with real pricing power; (3) switching costs in FinTech — Verafin (anti-financial-crime), AxiomSL (regulatory reporting), and Calypso (capital-markets/risk) are mission-critical, sticky, multi-year SaaS contracts banks do not rip out lightly. ARR +13% with SaaS at 38% quantifies the stickiness.
The trade-off is that Market Services remains cyclical — trading volumes ebb with market volatility — so the moat is wide but not fully insulated from the cycle.
Peer set (market cap): S&P Global $130B, CME Group $86B, Moody's $86B, Intercontinental Exchange (ICE) $75B, MSCI $44B, FactSet $8.9B. Against this exchange-and-data cohort, NDAQ sits mid-pack on multiple and growth: cheaper than MSCI/SPGI/MCO on forward earnings, more levered than most, and with a more software-tilted mix than pure-exchange ICE/CME. It is neither the cheapest nor the fastest — a quality name at a middling relative valuation.
9. Management, capital allocation & guidance
- Capital allocation: disciplined and shareholder-friendly — FY25 returned capital via $616M buybacks + $601M dividends, and in Q1'26 alone returned ~$700M ($548M repurchases, $153M dividends) with $2.9B remaining on the buyback authorization, while deleveraging. Capex is light (~3% of revenue). This is a textbook mature-compounder capital plan.
- Insider activity: mixed but not alarming. A routine EVP/CPO 10b5-1 sale (3,000 shares at $80, filed 2026-07-02) is offset by a 10%-owner Investor AB open-market purchase of 56,782 shares at $85.98 (2026-06-11) — a large, aligned holder buying near current levels is a mild positive signal. Director awards round out the recent Form 4 activity.
- Management's own guidance (half-weighted — their own book): the SEC 8-K earnings release (Q1'26, filed 2026-04-23) is a real earnings release with genuine forward guidance. Management's own words, half-weighted by house rule: FY2026 non-GAAP operating expense guidance $2.485–$2.545B, and non-GAAP tax rate 22.5–24.5% (maintained). CEO Adena Friedman framed it as "one of the strongest starts to the year in our company's history with broad-based growth across all three divisions"; CFO Sarah Youngwood cited "operating leverage with strong earnings growth" and explicitly "reducing leverage." Note this is expense/tax guidance, not a revenue or EPS target — management does not headline a full-year revenue number, so the forward EPS path in this note is analyst consensus, not company guidance.
10. Catalysts & what to watch
- Next earnings: 2026-07-23 (Q2'26; Street EPS $0.96, net revenue ~$1.42B). Watch ARR growth (holding ~13%?), FinTech organic growth, and index/ETP AUM inflows.
- Deleveraging cadence: net-debt/EBITDA trending down from 2.85× — each step lower supports a re-rating and de-risks the story.
- FinTech ACV bookings: Q1'26 bookings were +50% YoY with 80% cloud — sustaining that is the core of the growth thesis.
- Index inflows & AUM: the high-margin flywheel; $79B trailing-12-month net inflows and new BlackRock/State Street partnerships are the tell.
- Market volatility / volumes: the cyclical swing factor for Market Services — a volatility spike helps, a dead-calm tape hurts.
Thesis tripwires (what would change the call): ARR growth decelerating below ~10%; two consecutive quarters of FinTech booking softness; leverage rising rather than falling; or price breaking decisively below the 52-week low (~$77) on volume.
11. Key risks
- Leverage amplifies a downturn (structural): net-debt/EBITDA 2.85× means a volume/booking slump hits EPS harder than at un-levered peers. The single biggest risk multiplier.
- Cyclicality of Market Services: trading-volume-dependent revenue swings with market volatility and issuance/IPO cycles.
- Technical downtrend: −4.8% 12-mo vs SPY +20.6%; below both moving averages — the market is voting against the value thesis right now.
- Integration/execution: the software pivot (Adenza, Verafin) must keep delivering ARR growth to justify the "software, not exchange" re-rating; a stumble re-rates it back toward a plain exchange multiple.
- No expert corroboration: unlike higher-conviction Synthos names, zero KB voices cover NDAQ — the entire thesis rests on fundamentals and quant, with no independent-analyst cross-check.
- Goodwill/intangibles heavy: 76% of assets are goodwill+intangibles (Adenza/Verafin) — impairment risk if the software franchises underperform.
12. Verdict, position sizing & monitoring
Buy — Tactical. Nasdaq is a genuinely good business — a wide-moat, recurring-revenue financial-infrastructure compounder (ARR $3.2B +13%, FinTech +20%, 55% gross margin, $1.99B FCF) trading at a de-rated mid-teens forward multiple after a 16% drawdown. The base-case math (~$98, +16%) is constructive and the entire Street target range sits above today's price. But three things hold it back from Core: (1) elevated leverage (2.85×) in a partly cyclical model; (2) a live technical downtrend underperforming both SPY and QQQ; and (3) no expert corroboration in our KB. That combination is a tactical value-compounder setup — buy it for the re-rating, but scale in and respect the price action.
- Sizing: satellite / value-compounder, ~2–3% — a re-rating candidate to accumulate, not a core conviction position. Given the downtrend, scale in (starter now, adds on a reclaim of the ~$88 50-DMA or a hold of the ~$77 low).
- Monitoring: re-underwrite on the §10 tripwires; formal re-score each earnings print. This verdict is logged as a tracked Synthos call as of 2026-07-03 at $84.66.
- Single biggest risk: a market-volume/booking slowdown colliding with the balance-sheet leverage while the stock is already out of favor.
Provenance & disclosures
- Traceability: 0 KB claims — NDAQ has no expert coverage in the Synthos knowledge base. This note is explicitly fundamentals- and quant-driven; no conviction is borrowed or fabricated (claim-ID reconciliation is moot because there are no claims).
- Data as-of: fundamentals 2026-03-31 (Q1'26) · estimates & prices 2026-07-02/03 · no expert claims. Forward figures are analyst consensus (FMP), labeled as estimates.
- Reporting caveat: the data feed reports gross revenue (incl. transaction-based pass-throughs); management reports net revenue. We flag which basis is used throughout.
- Management caveat: Nasdaq's Q1'26 guidance (opex/tax) is management's own book, half-weighted by design, and covers expenses/tax — not revenue or EPS.
- Not investment advice. Independent research, educational and informational only, never personalized. Hypothetical/forward figures are labeled; the only performance numbers Synthos will headline are the live, real-money Flagship's.
- Version: 2026-07-03. Prior versions available via the deep-dive version dropdown ("based on the info at the time").